574744-39-1

Basic information

• Product Name: (S)-(-)-1-(4-METHOXYPHENYL)ETHYLAMINE-HCl
• Synonyms: (S)-(-)-1-(4-METHOXYPHENYL)ETHYLAMINE-HCl;(S)-(-)-1-(4-Methoxyphenyl)ethylaMine hydrochloride;(S)-1-(4-Methoxyphenyl)ethanamine hydrochloride;S-4-methoxy-α-methylbenzylamine hydrochloride
• CAS NO: 574744-39-1
• Molecular Formula: C9H14ClNO
• Molecular Weight: 187.66656
• Mol File: 574744-39-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (S)-(-)-1-(4-METHOXYPHENYL)ETHYLAMINE-HCl(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(-)-1-(4-METHOXYPHENYL)ETHYLAMINE-HCl(574744-39-1)
• EPA Substance Registry System: (S)-(-)-1-(4-METHOXYPHENYL)ETHYLAMINE-HCl(574744-39-1)

Safety Data

• Hazardous Substances Data: 574744-39-1(Hazardous Substances Data)

Usage

General Description

(S)-(-)-1-(4-METHOXYPHENYL)ETHYLAMINE-HCl is a chemical compound that belongs to the class of ethanolamines, a group of organic compounds that contain both an amine and an alcohol functional group. It is commonly used as a building block for the synthesis of other organic compounds, and it has potential applications in pharmaceutical research as a precursor for the preparation of various drugs and medications. The hydrochloride salt form of this compound, indicated by the "-HCl" suffix, makes it more stable and easier to handle in laboratory settings. It is important for researchers and chemists to handle this compound with care and follow proper safety protocols due to its potential reactivity and toxicity.

Upstream product

• 1515-95-3 p-ethylanisole 
• 2475-92-5 4-methoxyacetophenone oxime 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 768-60-5 4-methoxyphenylacetylen 
• 1164111-39-0 C₉H₁₁NO*ClH 
• 911372-64-0 (R_S)-N-((S)-1-(4-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 911372-63-9 (R_S)-N-((R)-1-(4-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 874291-46-0 (S)-N-(1-(4-methoxyphenyl)ethylidene)-2-methylpropane-2-sulfinamide 

Relevant articles and documents

Co-Catalyzed Synthesis of Primary Amines via Reductive Amination employing Hydrogen under very mild Conditions

Nanostructured and reusable 3d-metal catalysts that operate with high activity and selectivity in important chemical reactions are highly desirable. Here, a cobalt catalyst was developed for the synthesis of primary amines via reductive amination employing hydrogen as the reducing agent and easy-to-handle ammonia, dissolved in water, as the nitrogen source. The catalyst operates under very mild conditions (1.5 mol% catalyst loading, 50 °C and 10 bar H2 pressure) and outperforms commercially available noble metal catalysts (Pd, Pt, Ru, Rh, Ir). A broad scope and a very good functional group tolerance were observed. The key for the high activity seemed to be the used support: an N-doped amorphous carbon material with small and turbostratically disordered graphitic domains, which is microporous with a bimodal size distribution and with basic NH functionalities in the pores.

Donor Amine Salt-Based Continuous in situ-Product Crystallization in Amine Transaminase-Catalyzed Reactions

The unfavorable reaction equilibrium of transaminase-catalyzed reactions is a major challenge for the efficient biocatalytic synthesis of chiral amines. In this study the synthetic utilization of a salt-based, continuous in situ-product crystallization is

Reusable Nickel Nanoparticles-Catalyzed Reductive Amination for Selective Synthesis of Primary Amines

The preparation of nickel nanoparticles as efficient reductive amination catalysts by pyrolysis of in situ generated Ni-tartaric acid complex on silica is presented. The resulting stable and reusable Ni-nanocatalyst enables the synthesis of functionalized and structurally diverse primary benzylic, heterocyclic and aliphatic amines starting from inexpensive and readily available carbonyl compounds and ammonia in presence of molecular hydrogen. Applying this Ni-based amination protocol, -NH2 moiety can be introduced in structurally complex compounds, for example, steroid derivatives and pharmaceuticals.